Estonija - estonski - Ravimiamet

octapharma (ip) - humaanfibrinogeen - süste-/infusioonilahuse pulber ja lahusti - 1g 1tk

Europska Unija - estonski - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Estonija - estonski - Ravimiamet

aktsiaselts elme messer gaas - dilämmastikoksiid+hapnik - meditsiiniline surugaas - 50%+50% 2l 1tk; 50%+50% 15l 1tk; 50%+50% 10l 1tk; 50%+50% 5l 1tk

Europska Unija - estonski - EMA (European Medicines Agency)

advicenne s.a. - potassium citrate monohydrated, potassium hydrogen carbonate - acidosis, renal tubular - mineral supplements - sibnayal is indicated for the treatment of distal renal tubular acidosis (drta) in adults, adolescents and children aged one year and older.

Europska Unija - estonski - EMA (European Medicines Agency)

albireo - odevixibat - cholestasis, intrahepatic - vere ja maksa ravi - bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (pfic) in patients aged 6 months or older (see sections 4. 4 ja 5.

Estonija - estonski - Ravimiamet

csl behring gmbh - c1-inhibiitor, plasmast pärinev - süstelahuse pulber ja lahusti - 1500rÜ 1tk

Estonija - estonski - Ravimiamet

csl behring gmbh - c1-inhibiitor, plasmast pärinev - süste-/infusioonilahuse pulber ja lahusti - 500rÜ 1tk

Estonija - estonski - Ravimiamet

csl behring gmbh - c1-inhibiitor, plasmast pärinev - süstelahuse pulber ja lahusti - 3000rÜ 1tk; 3000rÜ 20tk

Estonija - estonski - Ravimiamet

csl behring gmbh - c1-inhibiitor, plasmast pärinev - süstelahuse pulber ja lahusti - 2000rÜ 5tk; 2000rÜ 20tk

Europska Unija - estonski - EMA (European Medicines Agency)

dipharma arzneimittel gmbh - sapropterin dihüdrokloriid - fenüülketonuria - muud alimentary seedetrakti ja ainevahetust tooted, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.